BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37023798)

  • 1. Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets.
    Katta SS; Nagati V; Paturi ASV; Murakonda SP; Murakonda AB; Pandey MK; Gupta SC; Pasupulati AK; Challagundla KB
    J Control Release; 2023 May; 357():444-459. PubMed ID: 37023798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapeutic targets for neuroblastoma.
    Aravindan N; Herman T; Aravindan S
    Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the developmental origin of neuroblastoma: an overview.
    Ponzoni M; Bachetti T; Corrias MV; Brignole C; Pastorino F; Calarco E; Bensa V; Giusto E; Ceccherini I; Perri P
    J Exp Clin Cancer Res; 2022 Mar; 41(1):92. PubMed ID: 35277192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quest to develop an effective therapy for neuroblastoma.
    Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
    J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
    Yang XH; Tang F; Shin J; Cunningham JM
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell death-based treatment of neuroblastoma.
    Valter K; Zhivotovsky B; Gogvadze V
    Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
    Czarnecka M; Trinh E; Lu C; Kuan-Celarier A; Galli S; Hong SH; Tilan JU; Talisman N; Izycka-Swieszewska E; Tsuei J; Yang C; Martin S; Horton M; Christian D; Everhart L; Maheswaran I; Kitlinska J
    Oncogene; 2015 Jun; 34(24):3131-43. PubMed ID: 25132261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
    Sabbih GO; Danquah MK
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma.
    Baldini F; Calderoni M; Vergani L; Modesto P; Florio T; Pagano A
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity.
    D'Amico S; Tempora P; Gragera P; Król K; Melaiu O; De Ioris MA; Locatelli F; Fruci D
    Front Immunol; 2023; 14():1268645. PubMed ID: 37849756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development.
    Tomolonis JA; Agarwal S; Shohet JM
    Cell Tissue Res; 2018 May; 372(2):245-262. PubMed ID: 29222693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
    Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
    BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State of the art in immunotherapy of neuroblastoma.
    Jabbari P; Hanaei S; Rezaei N
    Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
    Amoroso L; Haupt R; Garaventa A; Ponzoni M
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.
    Wang Y; Chen K; Cai Y; Cai Y; Yuan X; Wang L; Wu Z; Wu Y
    J Exp Clin Cancer Res; 2017 Aug; 36(1):111. PubMed ID: 28814318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution.
    Aravindan N; Subramanian K; Somasundaram DB; Herman TS; Aravindan S
    Cancer Drug Resist; 2019; 2(4):1086-1105. PubMed ID: 31867575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
    Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
    J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target.
    Yco LP; Geerts D; Mocz G; Koster J; Bachmann AS
    BMC Cancer; 2015 Jun; 15():477. PubMed ID: 26093909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.